FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W9635739> ?p ?o ?g. }

• W9635739 endingPage "4590" @default.
• W9635739 startingPage "4581" @default.
• W9635739 abstract "Abstract Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. However, T-cell depletion increases the risk of graft rejection. This study examined the use of CD52 monoclonal antibodies to eliminate T cells from both donor marrow and recipient to prevent both GVHD and rejection. Seventy patients receiving HLA-identical sibling transplants for acute myelogenous leukemia (AML) in first remission were studied. An IgM (CAMPATH-1M) was used for in vitro depletion of the graft and an IgG (CAMPATH-1G) for in vivo depletion of the recipient before graft infusion. No posttransplant immunosuppression was given. Results were compared with two control groups: (1) 50 patients who received bone marrow depleted with CAMPATH-1M, but no CAMPATH-1G in vivo; and (2) 459 patients reported to the International Bone Marrow Transplant Registry (IBMTR) who received nondepleted grafts and conventional GVHD prophylaxis with cyclosporin A (CyA) and methotrexate (MTX). The incidence of acute GVHD was 4% in the treatment group compared with 35% in the CyA/MTX group (P &lt; .001). Chronic GVHD was also exceptionally low in the treatment group (3% v 36%; P&lt; .001). The problem of graft rejection, which had been frequent in the historic CAMPATH-1M group (31%), was largely overcome in the treatment group (6%). Thus, transplant-related mortality of the treatment group (15% at 5 years) was lower than for the CyA/MTX group (26%; P = .04). There was little difference in the risk of leukemia relapse between the treatment group (30% at 5 years) and the CyA/MTX group (29%). Survival of the treatment group at 6 months was better than the CyA/MTX group (92% v 78%), although at 5 years the difference was not significant (62% v 58%) and neither was the difference in leukemia-free survival (60% v52%). We conclude that T-cell depletion is a useful strategy to prevent GVHD, provided that measures are taken to ensure engraftment. Using CAMPATH-1G to deplete residual host lymphocytes is a simple and practical method to do this. At least in AML, the beneficial reduction in GVHD can be achieved without an increased risk of relapse." @default.
• W9635739 created "2016-06-24" @default.
• W9635739 creator A5002578778 @default.
• W9635739 creator A5005246553 @default.
• W9635739 creator A5026694596 @default.
• W9635739 creator A5043585238 @default.
• W9635739 creator A5058361291 @default.
• W9635739 creator A5081336603 @default.
• W9635739 creator A5089096852 @default.
• W9635739 creator A5091433944 @default.
• W9635739 date "1998-12-15" @default.
• W9635739 modified "2023-10-16" @default.
• W9635739 title "Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection" @default.
• W9635739 cites W1274344746 @default.
• W9635739 cites W1492028808 @default.
• W9635739 cites W1976183578 @default.
• W9635739 cites W1982458543 @default.
• W9635739 cites W1994078412 @default.
• W9635739 cites W2001070274 @default.
• W9635739 cites W2006103885 @default.
• W9635739 cites W2013827273 @default.
• W9635739 cites W2015409036 @default.
• W9635739 cites W2021457023 @default.
• W9635739 cites W2029303244 @default.
• W9635739 cites W2032738293 @default.
• W9635739 cites W2050548746 @default.
• W9635739 cites W2050899871 @default.
• W9635739 cites W2054425626 @default.
• W9635739 cites W2069219892 @default.
• W9635739 cites W2069987316 @default.
• W9635739 cites W2075619062 @default.
• W9635739 cites W2076751769 @default.
• W9635739 cites W2079122731 @default.
• W9635739 cites W2083979433 @default.
• W9635739 cites W2086208070 @default.
• W9635739 cites W2091087368 @default.
• W9635739 cites W2117581174 @default.
• W9635739 cites W2128564651 @default.
• W9635739 cites W2151735361 @default.
• W9635739 cites W2154101238 @default.
• W9635739 cites W2318523525 @default.
• W9635739 cites W2404611980 @default.
• W9635739 cites W2408529386 @default.
• W9635739 cites W2410906370 @default.
• W9635739 cites W252642910 @default.
• W9635739 cites W3022109127 @default.
• W9635739 cites W4241194212 @default.
• W9635739 cites W4246835761 @default.
• W9635739 cites W4246839970 @default.
• W9635739 cites W74992319 @default.
• W9635739 cites W85233391 @default.
• W9635739 doi "https://doi.org/10.1182/blood.v92.12.4581" @default.
• W9635739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9845524" @default.
• W9635739 hasPublicationYear "1998" @default.
• W9635739 type Work @default.
• W9635739 sameAs 9635739 @default.
• W9635739 citedByCount "197" @default.
• W9635739 countsByYear W96357392012 @default.
• W9635739 countsByYear W96357392013 @default.
• W9635739 countsByYear W96357392014 @default.
• W9635739 countsByYear W96357392015 @default.
• W9635739 countsByYear W96357392016 @default.
• W9635739 countsByYear W96357392017 @default.
• W9635739 countsByYear W96357392018 @default.
• W9635739 countsByYear W96357392020 @default.
• W9635739 countsByYear W96357392021 @default.
• W9635739 countsByYear W96357392022 @default.
• W9635739 crossrefType "journal-article" @default.
• W9635739 hasAuthorship W9635739A5002578778 @default.
• W9635739 hasAuthorship W9635739A5005246553 @default.
• W9635739 hasAuthorship W9635739A5026694596 @default.
• W9635739 hasAuthorship W9635739A5043585238 @default.
• W9635739 hasAuthorship W9635739A5058361291 @default.
• W9635739 hasAuthorship W9635739A5081336603 @default.
• W9635739 hasAuthorship W9635739A5089096852 @default.
• W9635739 hasAuthorship W9635739A5091433944 @default.
• W9635739 hasConcept C126322002 @default.
• W9635739 hasConcept C141071460 @default.
• W9635739 hasConcept C203014093 @default.
• W9635739 hasConcept C2778384904 @default.
• W9635739 hasConcept C2778461978 @default.
• W9635739 hasConcept C2779015954 @default.
• W9635739 hasConcept C2779972918 @default.
• W9635739 hasConcept C2780007613 @default.
• W9635739 hasConcept C2780252810 @default.
• W9635739 hasConcept C2781059491 @default.
• W9635739 hasConcept C2911091166 @default.
• W9635739 hasConcept C71924100 @default.
• W9635739 hasConcept C90924648 @default.
• W9635739 hasConceptScore W9635739C126322002 @default.
• W9635739 hasConceptScore W9635739C141071460 @default.
• W9635739 hasConceptScore W9635739C203014093 @default.
• W9635739 hasConceptScore W9635739C2778384904 @default.
• W9635739 hasConceptScore W9635739C2778461978 @default.
• W9635739 hasConceptScore W9635739C2779015954 @default.
• W9635739 hasConceptScore W9635739C2779972918 @default.
• W9635739 hasConceptScore W9635739C2780007613 @default.
• W9635739 hasConceptScore W9635739C2780252810 @default.

• next